Agreement expands Jupiter from a single-program company into a dual clinical-stage CNS developer. Management believes the transaction strengthens the Company through diversification across two-clinical-stage CNS assets; expanding its portfolio to include both its natural resveratrol program and a Novel Chemical Entity; near term clinical milestones; and long-term participation in U.S commercialization opportunity through perpetual exclusive rights.

Transaction Highlights

• Deal Value: Up to $100M (including milestone payments; exclusive of ongoing royalties)
• Upfront Payment: $3.3M ($1.5M cash + $1.8M JUNS common stock, 120-day lock-up)
• Development Milestone: $3.3M upon Phase 3 First Patient In
• Regulatory Milestone: $20M upon U.S. NDA Approval
• Commercial Milestones: $10M / $30M / $33.3M at $333M / $1B / $2B cumulative U.S. net sales
• Royalty: 3% of net sales (commencing after third commercialization milestone)
• Asset: ALA-002 — FDA NCE-designated, non-racemic MDMA (patented)
• Rights Granted: Perpetual, exclusive to United States
   

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.